New 3D platform aims to steady the steps of Parkinson's and stroke patients
NCT ID NCT07502937
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test a special moving platform combined with virtual reality to help people with neurological disorders like Parkinson's disease, stroke, ALS, or mild cognitive impairment improve their balance and movement. The platform moves in three directions and adapts exercises in real time. The study includes 45 patients and 15 healthy volunteers to first check safety and usability, then see if it helps with balance, thinking, and quality of life compared to standard rehab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients: adults aged 18 to 80 years. * Patients: confirmed diagnosis of one of the following chronic neurological conditions: stroke, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or mild cognitive impairment (MCI). * Patients: able to understand and follow study procedures and provide informed consent. * Healthy volunteers: adults aged 18 to 65 years. * Healthy volunteers: able to understand and follow study procedures and provide informed consent. * Healthy volunteers: rehabilitation staff members from the participating centers. Exclusion Criteria: * Patients: severe psychiatric disorders or cognitive disorders that impair the ability to complete cognitive tests and self-report questionnaires. * Patients: unable to provide informed consent. * Patients: moderate to severe cognitive impairment, defined as an ECAS score below 81.92 in participants with ALS or a Raven's Matrices score below 18.36 in participants with mild cognitive impairment. * Patients: neurological or physical conditions that significantly limit lower-limb use and prevent standing on the platform, including lower-limb muscle strength of 3 or less on the Medical Research Council (MRC) scale. * Patients: body weight greater than 100 kg. * Patients: current or recent participation, within the last 3 months, in other rehabilitation programs or interventions that could affect study results. * Patients: alcohol or substance dependence that could compromise safety during training sessions. * Patients: unstable health conditions that could make use of the 3DoF Platform and/or head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions. * Healthy volunteers: health conditions that could make use of the 3DoF Platform and/or head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions. * Healthy volunteers: any motor disability.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Robot Co-Pilot could steer wheelchairs away from collisions
- Can a NAD-Boosting supplement slow ALS? extension trial tests nicotinamide riboside and pterostilbene
- Spinal cord stimulation put to the test for Parkinson's freezing of gait
- Robot could let stroke patients rehab their hands at home without a therapist
- Breathing support in ALS: what it means for patients and families